Nasal Pneumococcal Vaccine Ab-01.12 Clears Ethics Review for First Human Trial

0 points · first seen 2h ago · 1 outlet · 0 comments

Nasal pneumococcal vaccine Ab-01.12 has cleared Dutch CCMO ethics review and will enter its first human Phase I trial at Radboud UMC, targeting conserved proteins shared across all serotypes via outer membrane vesicle technology -- the first intranasal approach in pneumococcal vaccine history and a potential answer to serotype replacement. — Tech Times

save

· share to X · Bluesky · copy link